Bispecific (T-cell engager)An antibody that binds a myeloma target and a T cell, so the T cell attacks the myeloma.
BCMA, GPRC5DProteins on myeloma cells that these drugs target.
CAR-TThe patient's own T cells, engineered to recognize myeloma.
CRS, ICANSCytokine release syndrome and immune-cell-associated neurotoxicity, the main early side effects.
≥CR, VGPRComplete response or better; very good partial response.
MRDMeasurable residual disease: myeloma still detectable by sensitive tests.
PFS, OS, HRProgression-free survival, overall survival and hazard ratio (below 1 favors the new treatment).
EMDExtramedullary disease: myeloma growing outside the bone marrow.